Congress Materials – 25th World Congress of Psychiatry (WCP 2025)
2025 25th World Congress of Psychiatry | Oct 5-8 | Prague, Czech Republic
This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.
Adjunctive Lumateperone 42 mg in the Treatment of Major Depressive Disorder: A Pooled Analysis of 2 Phase 3 Randomized Controlled Trials
Suresh Durgam, Willie R. Earley, Susan G. Kozauer, Changzheng Chen, John B. Edwards, Rakesh Jain, Christoph U. Correll
Adjunctive Lumateperone in Patients With Major Depressive Disorder and Anxious Distress
Susan G. Kozauer, Suresh Durgam, Willie R. Earley, Yifan Mo, John B. Edwards, Rakesh Jain
Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.
